GlyCosmos Glycolipids
Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
| Database | Last Updated |
|---|---|
| ChEBI | February 3, 2022 |
| KEGG | February 3, 2022 |
| LIPID MAPS Structure Database | February 3, 2022 |
| LipidBank | February 3, 2022 |
| PubChem | February 3, 2022 |
| Main Class | Sub Class | LM ID | Common Name | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass | Formula ▼ |
|---|---|---|---|---|---|---|---|---|---|
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
2053.144626
|
C96H172N4O42
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II A antigen(d18:1/24:0)
|
2053.144626
|
C96H172N4O42
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
2053.144626
|
C96H172N4O42
|
||||||
|
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)
|
2121.107968
|
C96H172N2O48
|
||||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
2082.13479
|
C96H171N5O43
|
||||||
|
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
2082.13479
|
C96H171N5O43
|
||||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Ley-A-9(d18:1/20:0)
|
2086.118472
|
C96H171N3O45
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
trimeric LeY-9(d18:1/20:0)
|
2086.118472
|
C96H171N3O45
|
|||||
|
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)
|
globo-Lex-9(d18:1/26:1(17Z))
|
2038.133727
|
C96H171N3O42
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II B antigen(d18:1/26:1(17Z))
|
2038.133727
|
C96H171N3O42
|
Displaying entries 161 - 170 of 6008 in total
To see the latest features, please visit our beta site.
International Collaboration
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Acknowledgements
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
